DLBCL, NOS GENETIC SUBTYPES
Clinical trials for DLBCL, NOS GENETIC SUBTYPES explained in plain language.
Never miss a new study
Get alerted when new DLBCL, NOS GENETIC SUBTYPES trials appear
Sign up with your email to follow new studies for DLBCL, NOS GENETIC SUBTYPES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on tough lymphoma in early trial
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy for adults with large B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are to find a …
Matched conditions: DLBCL, NOS GENETIC SUBTYPES
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 24, 2026 02:46 UTC
-
New combo attack on tough lymphoma shows promise in early trial
Disease control OngoingThis phase 2 study tests whether combining the drug acalabrutinib with a CAR T-cell therapy called lisocabtagene maraleucel (liso-cel) can help people with aggressive B-cell lymphoma that has come back or not responded to treatment. About 28 adults will receive the combination. T…
Matched conditions: DLBCL, NOS GENETIC SUBTYPES
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC